

Supplementary Table 1. The prevalence of cancer among patients with membranous nephropathy in previous studies

Author	Year	Number of patients	Neoplasia/total %	Type of cancer
Row et al.	1975	66	11	Bronchial, Colon-rectum, Hodgkln's, Leukaemia, Wilm's
Chavaz et al.	1977	92	8	NA
Noel et al.	1979	140	1	NA
Zech et al.	1982	30	22	NA
Kingswood et al.	1984	24	12	NA
Abe et al.	1986	137	1.5	NA
Cahen et al.	1989	82	3.2	NA
Burstein et al.	1993	107	8	Lung, Breast, Bladder, Bile duct
Rihova et al.	2005	129	6.2	Lung, Colon, Prostate
LeFaucheur et al.	2006	240	10	Lung, Stomach, Prostate
Bjørneklett et al.	2007	161	20.5	Lung, Colon-rectum, Prostate
Zeng et al.	2008	390	3.1	Light chain deposit disease, Thyroid, Gastrointestinal, Mediastinal
Lönnbro-Widgren et al.	2015	210	8.1	Prostate, Lung, Colon, Lymphoma Uterus, Leukaemia, Buccal, Breast
Alnasrallah et al.	2017	201	21.4	Lung, Colon, Prostate, Intestine, Kidney, Leukaemia, Pancreatic, Cervical, Bile duct

NA=not analysis

Supplementary Table 2. Glomerular PLA2R deposits or circulatory anti-PLA2R antibodies in malignancy associated MN in previous studies

Author	Year	Method	Number of patients with malignancy associated MN	Positive glomerular staining or serum antibodies patients (%)
Qin et al.	2011	Serum antibody (WB)	10	3 (30)
Hoxha et al.	2012	Tissue staining	7	0
Larsen et al.	2013	Tissue staining	12	3 (25)
Oh et al.	2013	Serum antibody (WB)	2	1 (50)
Akiyama et al.	2014	Serum antibody (WB)	6	0
Hayashi et al.	2014	Tissue staining, Serum antibody (WB)	1	0
Timmermans et al.	2014	Serum antibody (ELISA)	3	0
Iwakura et al.	2015	Tissue staining	8	1
Dong et al.	2016	Tissue staining	2	2 (100)
Hihara et al.	2016	Tissue staining, Serum antibody (ELISA)	2	0
Wei et al.	2016	Tissue staining, Serum antibody (ELISA)	6	0
Pourcine et al.	2017	Tissue staining, Serum antibody (ELISA)	10	2 (20)
Wang et al.	2017	Tissue staining, Serum antibody (ELISA)	44	18 (41)

Supplementary Table 3. Glomerular THSD7A deposition or circulating THSD7A antibodies in MN with cancer in previous studies

Author	Year	Number of patients with THSD7A associated MN	Positive patients with malignancy (%)
Iwakura et al.	2015	5	0
Hoxha et al.	2015	40	8 (20)
Wang et al.	2017	13	1 (7.7)
Sharma et al.	2017	31	2 (6)